Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL)
NCT00086203 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL
Last updated 2015-03-25
Summary
The objective of this study is to assess the efficacy and safety of talabostat and rituximab in patients with advanced CLL who failed to respond, or have progressed following a prior response, to a fludarabine regimen.
Conditions
Interventions
- DRUG
-
Talabostat mesylate (PT-100) tablets
- DRUG
Sponsors & Collaborators
-
Point Therapeutics
lead INDUSTRY
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Completion
- 2007-09-30
Countries
- United States
Study Locations
More Related Trials
-
Etanercept and Rituximab in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
NCT00201682 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
NCT04680052 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma
NCT00049413 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL
NCT01203930 ·Status: TERMINATED ·Phase: PHASE2
-
Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL)
NCT01446133 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery
NCT02160015 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT06521255 ·Status: RECRUITING ·Phase: PHASE3
-
Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLL
NCT00543114 ·Status: TERMINATED ·Phase: PHASE1
-
CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b)
NCT01998880 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of MabThera (Rituximab) Plus Chlorambucil in Participants With Chronic Lymphocytic Leukemia.
NCT00532129 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia (CLL) That Did Not Respond to Fludarabine, CLL With Autoimmune Haemolytic Anemia (AIHA) or Richter's Transformation (RT)
NCT00309881 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Dasatinib and Rituximab for Relapsed/Refractory Chronic Lymphocytic Leukemia
NCT00949988 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation
NCT02535286 ·Status: COMPLETED ·Phase: PHASE1
-
Rituximab Neoadjuvant Therapy in Patients With Prostate Cancer Scheduled to Undergo Radical Prostatectomy
NCT01804712 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Lenalidomide and Rituximab in the Treatment of Relapsed Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma
NCT00294632 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab)
NCT01418430 ·Status: COMPLETED ·Phase: PHASE4
-
Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
NCT01754870 ·Status: WITHDRAWN ·Phase: PHASE2
-
S0213 Chemotherapy Plus Rituximab in Treating Patients With Mantle Cell Lymphoma
NCT00041132 ·Status: COMPLETED ·Phase: PHASE2
-
Cladribine and Rituximab as Remission Induction Therapy Followed By Rituximab and Stem Cell Mobilization in Treating Patients With CLL
NCT00072007 ·Status: COMPLETED ·Phase: PHASE2
-
Pentostatin and Rituximab in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
NCT00026351 ·Status: COMPLETED ·Phase: PHASE2
-
Ribomustin in the First Line Therapy of Chronic Lymphocytic Leukemia
NCT02110394 ·Status: COMPLETED
-
Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)
NCT00628238 ·Status: UNKNOWN ·Phase: PHASE2
-
Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL
NCT01754857 ·Status: COMPLETED ·Phase: PHASE2
-
Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma
NCT04189952 ·Status: TERMINATED ·Phase: PHASE2
-
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
NCT01886872 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3